Pfizer Inc. Stock
€20.57
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income-seeking
Pfizer Stock: Billion-Dollar Chinese Cancer Drug Deal
Pharmaceutical giant Pfizer is making significant strategic moves in oncology, investing up to $6 billion in a licensing deal with Chinese biotech firm 3SBio. The agreement centers on SSGJ-707, a
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green in 2025 as of the Apr. 21 close. Shares were down
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in
Pfizer Stock: Probe Into COVID Vaccine Timing Claims
Pfizer shares are facing significant pressure following reports that Manhattan federal prosecutors are investigating serious allegations. The inquiry centers on claims made by British pharmaceutical
Pfizer Stock: Company Sells Entire Haleon Stake
Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per
Pfizer Stock: Shares Drop Despite Cancer Drug Progress
Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid
Pfizer Stock: Nearing 52-Week Lows Amid Challenges
Pfizer's stock currently faces a challenging market position, trading precariously close to its 52-week lows. The shares recently showed minimal recovery, rising just 0.2 percent to $25.99 in New
Pfizer Stock: Court Ruling Clouds Positive Momentum
Pfizer shares gained 0.9 percent on Wednesday in New York trading, closing at $25.98 after reaching an intraday high of $26.17. Investor interest remained strong with over one million shares
Pfizer Stock: Cancer Drug Study Shows Promising Results
Pfizer and Astellas Pharma have achieved a significant breakthrough in advanced bladder cancer treatment, demonstrating remarkable success with their combination therapy of PADCEV and KEYTRUDA. The
Pfizer Stock: Quarterly Results Show Strong Recovery Signs
Pfizer's recent quarterly performance demonstrates a significant turnaround, with revenues surging nearly 25% to reach $17.76 billion. The pharmaceutical giant has shown remarkable improvement in
Pfizer Stock: Q4 Surge Despite Market Dip
Pfizer's stock experienced a modest decline of 0.8% to $26.24 in Thursday's New York trading session, yet the pharmaceutical giant's underlying performance tells a more compelling story. The company
Pfizer Stock: AI Partnership Drives Strategic Transformation
Pharmaceutical giant Pfizer is embarking on a significant strategic shift with a heightened focus on artificial intelligence through a multi-year collaboration with technology firm Data4Cure. This
Pfizer Stock: Cancer Drug Study Shows Promising Results
Pfizer's recent breakthrough in cancer research is painting a promising picture for the pharmaceutical giant, despite its stock experiencing a slight dip of 0.9% to $26.27. The company has achieved
Top 3 Stocks Seeing a Spike in Call Option Volume
Volume is what drives the entire market, and that is a fact that often gets lost in the sea of indicators, patterns, and trend lines that dominate today’s concept of analysis. However, most
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to slide right back down
Why BioNTech Stock Soared Today
BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news
Terrible News for Pfizer Stock Investors
The past three years have been challenging for Pfizer (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.
However
Down 63%, Should You Buy the Dip on Pfizer?
It's been a tough go for Pfizer (NYSE: PFE). Shares of the pharmaceutical giant are down over 60% from their highs, a multi-year slide since pandemic-related sales peaked a few years ago. But that's
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
Most people like to buy products when prices are cheaper. That's why you'll probably see lots of car dealers, furniture stores, and retailers advertising special sales during the Memorial Day
Pfizer Stock Analysis: Buy, Sell, or Hold?
Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities.
*Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.
2 High-Yield Dividend Stocks to Buy Right Now
Though there are plenty of dividend stocks on the market, they aren't all created equal. Consider that the average dividend yield for the S&P 500 (SNPINDEX: ^GSPC) is 1.3%, which is not particularly
Here's How Many Shares of Pfizer You Should Own to Make $10,000 in Annual Dividend Income
Looking for income? You might want to check out Pfizer (NYSE: PFE). This big drugmaker has been a favorite for income investors for years. However, its dividend is arguably more attractive than
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Recently, the Trump Administration signed an executive order to lower the prices Americans pay for prescription drugs. According to the administration, the U.S. funds roughly 75% of global